Table 2. Outcomes of out-of-hospital cardiac arrest during meeting and non-meeting days.
| Meeting days | Non-meeting days | P | |
| Whole arrests | |||
| 1-month survival, % (n/N) | 3.8 (774/20 143) | 3.8 (1477/38 859) | |
| Crude OR (95% CI) | 1.01 (0.93–1.11) | Reference | 0.802 |
| Adjusted OR (95% CI) | 1.01 (0.92–1.11) | Reference | 0.799 |
| Favorable neurologic outcome, % (n/N) | 1.6 (324/20 142) | 1.5 (596/38 855) | |
| Crude OR (95% CI) | 1.05 (0.92–1.08) | Reference | 0.488 |
| Adjusted OR (95% CI) | 1.02 (0.88–1.19) | Reference | 0.757 |
| Bystander-witnessed VF arrests with cardiac origin | |||
| 1-month survival, % (n/N) | 28.9 (275/951) | 26.5 (481/1814) | |
| Crude OR (95% CI) | 1.12 (0.94–1.35) | Reference | 0.179 |
| Adjusted OR (95% CI) | 1.10 (0.92–1.33) | Reference | 0.297 |
| Favorable neurologic outcome, % (n/N) | 19.1 (182/951) | 17.9 (324/1813) | |
| Crude OR (95% CI) | 1.09 (0.89–1.33) | Reference | 0.413 |
| Adjusted OR (95% CI) | 1.04 (0.83–1.29) | Reference | 0.750 |
CI, confidence interval; OR, odds ratio; VF, ventricular fibrillation.
ORs were adjusted for origin of arrest, gender, age, type of witnessed status, first documented rhythm, public-access AED shocks, dispatcher instruction, type of bystander CPR, intravenous fluid, epinephrine, advanced airway management, hospital arrival time, day of week, time of day, and year.
A total of 155 1-month survival and 160 favorable neurologic outcome data points were missing.